Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Common Equity (2016 - 2025)

Historic Common Equity for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $598.4 million.

  • Celldex Therapeutics' Common Equity fell 2386.32% to $598.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.4 million, marking a year-over-year decrease of 2386.32%. This contributed to the annual value of $747.0 million for FY2024, which is 7405.77% up from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Common Equity is $598.4 million, which was down 2386.32% from $655.4 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Common Equity ranged from a high of $838.6 million in Q1 2024 and a low of $182.3 million during Q2 2021
  • Moreover, its 5-year median value for Common Equity was $419.5 million (2021), whereas its average is $477.1 million.
  • Per our database at Business Quant, Celldex Therapeutics' Common Equity tumbled by 2857.37% in 2023 and then skyrocketed by 21854.38% in 2024.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Common Equity stood at $419.5 million in 2021, then decreased by 22.24% to $326.2 million in 2022, then surged by 31.57% to $429.2 million in 2023, then skyrocketed by 74.06% to $747.0 million in 2024, then dropped by 19.9% to $598.4 million in 2025.
  • Its Common Equity was $598.4 million in Q3 2025, compared to $655.4 million in Q2 2025 and $703.0 million in Q1 2025.